课题基金 / 基金详情

Developing novel animal cell lines and processes incoperating engineered caf1 to scale cultured meat protein manufacturing

Developing novel animal cell lines and processes incoperating engineered caf1 to scale cultured meat protein manufacturing
开发新型动物细胞系和工艺,与工程化 caf1 相结合,以扩大培养肉蛋白生产规模
批准号:
10076199
负责人:
金额:
$31.65万
依托单位:
依托单位国家:
英国
项目类别:
Collaborative R&D
财政年份:
2023
资助国家:
英国
项目状态:
未结题
起止时间:
2023 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
World meat consumption has tripled since 1970 and will increase a further 76% by 2050, posing a significant sustainability challenge. Livestock farming contributes to 15% of human-made greenhouse gas (GHG) emissions, which further exacerbates climate change, environmental destruction, and infectious disease outbreaks. Cultivated meat (CM) is an approach that rather than utilising animal agriculture as a source of proteins for human consumption, uses cell-based technologies to grow protein in a slaughter-free way. CM requires fewer resources, including energy, land, and water, and generates fewer GHG emissions compared to traditional livestock farming. It also eliminates concerns related to animal welfare and excessive antibiotic use. The major barriers preventing this approach from entering the consumer market relate to a mixture of economic and technical barriers. For this technological approach to be realized three principle components are needed, cells, growth media, and machines. This project seeks to develop panels of cell lines (the starting basis of all cultivated meat, Unicorn Bio, Trading as Dragon Bio) that will be released for sale to cultivated meat R&D tool developers and commercial manufacturers. Furthermore, we seek to develop growth media additives (MarraBio) that, simultaneously, significantly extend the variety of cell types amenable to be manufactured at industrial scales and vastly reduce the cost of such production. Thereby enabling the industry to move towards techno-economic feasibility, as well as the mass manufacture and consumer market entry of such products
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
Novel-miR-1134调控LHCGR的表达介导拟 穴青蟹卵巢发育的机制研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2025
  • 负责人:
    崔文晓
  • 依托单位:
novel-miR75靶向OPR2,CA2和STK基因调控人参真菌胁迫响应的分子机制研究
  • 批准号:
    82304677
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30.00万元
  • 批准年份:
    2023
  • 负责人:
    边兴博
  • 依托单位:
海南广藿香Novel17-GSO1响应p-HBA调控连作障碍的分子机制
  • 批准号:
    82304658
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30万元
  • 批准年份:
    2023
  • 负责人:
    刘亚
  • 依托单位:
白术多糖通过novel-mir2双靶向TRADD/MLKL缓解免疫抑制雏鹅的胸腺程序性坏死
  • 批准号:
    32102747
  • 项目类别:
    青年科学基金项目(C类)
  • 资助金额:
    30.0万元
  • 批准年份:
    2021
  • 负责人:
    李婉雁
  • 依托单位: